Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
The experimental anticoagulant's win over aspirin in patients intolerant to or unsuitable for warfarin therapy may allow a narrower indication.